Shilpa Medicare launches Lenvatinib Capsules in India under the brand name Lenshil
The company is already marketing the 4 mg and 10 mg strengths
The company is already marketing the 4 mg and 10 mg strengths
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Mix-n-Stain CF Dye IgM Antibody Labeling Kits address longstanding challenges for labeling IgM antibodies by offering efficient and convenient conjugation with bright CF Dyes
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
Subscribe To Our Newsletter & Stay Updated